News & Updates
Showing Endocrinology articles
Showing
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).
Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS
In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.
Insulin resistance, fertility outcomes favour carnitine in PCOS
Carnitine appears to be beneficial in the treatment of women with polycystic ovary syndrome (PCOS), with the drug helping improve ovulation, clinical pregnancy, insulin resistance, and body mass index, according to the results of a meta-analysis.
SGLT-2I–MRA combo yields maximal kidney, cardiovascular protection in T2DM, CKD
Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.
Obesity, metabolic dysfunction linked to BPE in premenopausal women
A recent study has established the association of increased background parenchymal enhancement (BPE) with obesity, insulin resistance, leptin, and adiponectin in premenopausal women who are at high risk of breast cancer.
Diet, physical activity help lower cardiometabolic disease risk
Behavioural weight-loss interventions, such as diet alone and diet plus physical activity (PA), induce a beneficial change in biomarkers of insulin resistance and cardiometabolic health in adults with overweight or obesity, reports a study. However, no additional benefit has been observed with the addition of moderate-intensity PA to a diet-only intervention.
Adipose tissue–targeted nanoparticles may improve treatment of obesity and atherosclerosis
Researchers from the University of Hong Kong (HKU) have developed a nanoparticle-based targeted drug delivery system that selectively transports thyroid hormone (TH) to adipose tissue, which may improve treatment of obesity and its related cardiometabolic complications by overcoming serious adverse events (AEs) associated with systematic TH administration.